Ethical issues

Prenatal Medicine

Volumn , Issue , 2016, Pages 575-604

  De Wert, Guido ^a   Dondorp, Wybo ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85051689671     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (155)

1. Council of Europe. Recommendation No. R(90) 3 on Prenatal Genetic Screening, Prenatal Genetic Diagnosis and Associated Genetic Counseling, 1990.
2. Group of Advisers on the Ethical Implications of Biotechnology of the European Commission. Opinion No. 6: Ethical Aspects of Prenatal Diagnosis, 1996.
3. McNally C, et al. Ethical, legal and social aspects of genetic testing: research, development and clinical applications. Brussels European Commission. Community Res. 2004.
4. De Wert GM. Reproductive technology, genetics and ethics (in Dutch). Thesis, Amsterdam, Thela, 1999.
5. Health Council of the Netherlands. Heredity: Science and Society. The Hague: Health Council of the Netherlands, 1989.
6. Medical Ethics Today. The BMA's Handbook of Ethics and Law. London: Br Med J Publishing Group, 2004.
7. Evers-Kiebooms G, Zoetewij MW, Harper PS, eds. Prenatal Testing for Late-onset Neurogenetic Disease. Oxford: BIOS, 2002.
8. Nys H, Roemo Casabona CM, Desmet C. Legal aspects of prenatal testing for lateonset neurological diseases. In: Evers-Kiebooms G, Zoetewij MW, Harper PS, eds. Prenatal Testing for Late-onset Neurogenetic Disease. Oxford: BIOS, 2002:83-106.
9. Minister of Public Health of the Netherlands. Prenatal Diagnosis. Letter to Parliament, dated March 4, 1996 (in Dutch).
10. De Wert GM. Ethical aspects of prenatal testing and preimplantation genetic diagnosis for late-onset neurogenetic disease: the case of Huntington's disease. In: Evers-Kiebooms G, Zoetewij MW, Harper PS, eds. Prenatal Testing for Late-onset Neurogenetic Disease. Oxford: BIOS, 2002:129-158.
11. Adam S, Wiggins S, Whyte P, et al. Five year study of prenatal testing for Huntington's disease: demand, attitudes, and psychological assessment. J Med Genet 1993; 30(7):549-556.
12. Simpson SA, Harper PS. Prenatal testing for Huntington's disease: experience within the UK 1994-1998. J Med Genet 2001; 38(5):333-335.
13. International Huntington Association and World Federation of Neurology. Guidelines for the molecular genetics predictive test in Huntington's disease. Neurology 1994; 44(8):1533-1536.
14. Tassicker R, Savulescu J, Skene L, Marshall P, Fitzgerald L, Delatycki MB. Prenatal diagnosis requests for Huntington's disease when the father is at risk and does not want to know his genetic status: clinical, legal, and ethical viewpoints. Br Med J 2003; 326(7384):331-333.
15. Lucassen AM, Houlston RS. Clinical geneticists' attitudes and practice towards testing for breast cancer susceptibility genes. J Med Genet 2000; 37(2):157-160.
16. Royal Dutch Society of Physicians. Doctors and Genes (in Dutch). Utrecht: Royal Dutch Society of Physicians, 1997.
17. Cobben JM, Broecker AHJT, Leschot NJ. Prenatale diagnostiek naar de erfelijke aanleg voor mamma-/ovariumcarcinoom-een standpuntbepaling. Ned Tijdschr Geneeskd 2002; 146:1461-1465.
18. Meijers-Heijboer H, van Geel B, van Putten WL, et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2001; 345(3):159-164.
19. Brambati B, Formigli L, Mori M, Tului L. Multiple pregnancy induction and selective fetal reduction in high genetic risk couples. Hum Reprod 1994; 9(4):746-749.
20. Evans MI, Dommergues M, Wapner RJ, et al. International, collaborative experience of 1789 patients having multifetal pregnancy reduction: a plateauing of risks and outcomes. J Soc Gynecol Investig 1996; 3(1):23-26.
21. Nuffield Council on Bioethics. Genetics and Human Behaviour. London: Nuffield Council on Bioethics, 2002.
22. Stein E. Choosing the sexual orientation of children. Bioethics 1998; 12(1):1-24.
23. Ten CL. The use of reproductive technologies in selecting the sexual orientation, the race, and the sex of children. Bioethics 1998; 12(1):45-48.
24. De Wert GM. Prenatal testing and selection; proceed with caution. In: Galjaard H, Noor LHW, eds. Prenatal Testing. New Developments and Ethical Dilemmas. Amsterdam:Royal Netherlands Academy of Sciences, 2003:61-68.
25. Warren MA. Gendercide. In: The implications of sex selection. Totowa, NJ: Rowman and Allenheld, 1985.
26. Embryo Protection Act (Germany; BGBI.I S.2746). 1990.
27. Law on Medically Assisted Reproduction (Italy). 2004.
28. Nationaler Ethikrat. Stellungnahme. Genetische Diagnostik vor und während der Schwangerschaft, 2003.
29. Loi relative au don et à utilisation des elements et produits du corps humain, à l'assistance medicale à la procreation et au diagnostic prenatal (L94-654), Revisee 2004 (L2004-800), 2004.
30. Human Fertilisation and Embryology Authority. Outcome of the public consultation on preimplantation genetic diagnosis. London HGC, 2001.
31. Planningsbesluit klinisch genetisch onderzoek en erfelijkheidsadvisering, 2003.
32. Verlinsky Y, Rechitsky S, Verlinsky O, Masciangelo C, Lederer K, Kuliev A. Preimplantation diagnosis for early-onset Alzheimer disease caused by V717L mutation. J Am Med Assoc 2002; 287(8):1018-1021.
33. Human Fertilisation and Embryology Act. 1990, UK.
34. Health Council of the Netherlands. IVF related research. Pre-implantation genetic diagnosis, Research concerned with improving IVF, Research using human embryos. Evaluation. Rijswijk: Health Council of the Netherlands, 1998.
35. O'Neill O. Autonomy and trust in bioethics. Cambridge: Cambridge University Press, 2002.
36. Schulman JD, Black SH, Handyside A, Nance WE. Preimplantation genetic testing for Huntington disease and certain other dominantly inherited disorders. Clin Genet 1996; 49(2):57-58.
37. Braude PR, De Wert GM, Evers-Kiebooms G, Pettigrew RA, Geraedts JP. Nondisclosure preimplantation genetic diagnosis for Huntington's disease: practical and ethical dilemmas. Prenat Diagn 1998; 18(13):1422-1426.
38. Shenfield F, Pennings G, Devroey P, Sureau C, Tarlatzis B, Cohen J. Taskforce 5:preimplantation genetic diagnosis. Hum Reprod 2003; 18(3):649-651.
39. De Wert GM. Preimplantation genetic diagnosis: the ethics of ''intermediate'' cases. Hum Reprod 2005; 20(12): 3261-3266.
40. Pennings G, de Wert G. Evolving ethics in medically assisted reproduction. Hum Reprod Update 2003; 9(4):397-404.
41. KearneyW, Caplan AC. Parity for donation of bone marrow. In: Blank RH, Bonnicksen AL, eds. Emerging Issues in Biomedical Policy. An Annual Review Vol. 1. New York:Columbia University Press, 1992:262-285.
42. Human Fertilisation and Embryology Authority. HFEA agrees to extend policy on tissue typing. 21-7-2004, Press Release.
43. Council of Europe. Convention on Human Rights and Biomedicine. Directorate of Legal Affairs, Strasbourg, 1996.
44. Warnock Report. Report of the Committee of Inquiry into Human Fertilisation and Embryology. London: Her Majesty's Stationary Office, 1984.
45. Health Council of the Netherlands. Sex Selection for Non-medical Reasons. The Hague:Health Council of the Netherlands, 1995.
46. Embryo Act (The Netherlands), 2002.
47. Human Fertilisation and Embryology Authority. Sex Selection: Options for Regulation. A Report on the HFEA's 2002-2003 Review of Sex Selection Including Discussion of Legislative and Regulatory Options. London: HFEA, 2003.
48. Dahl E. The presumption in favour of liberty: a comment on the HFEA's public consultation on sex selection. Reprod Biomed Online 2004; 8(3):266-267.
49. Pennings G. Ethics of sex selection for family balancing.HumReprod 1996; 11:2339-2345.
50. Robertson JA. Gender variety as a valid choice: a comment on the HFEA response to Edgar Dahl's ''The presumption in favour of liberty''. Reprod Biomed Online 2004; 8(3):270-271.
51. Pickering SJ, Braude PR, Patel M, et al. Preimplantation genetic diagnosis as a novel source of embryos for stem cell research. Reprod Biomed Online 2003; 7(3):353-364.
52. de Wert G, Mummery C. Human embryonic stem cells: research, ethics and policy. Hum Reprod 2003; 18(4):672-682.
53. Wilson JMG, Jungner G. Principles and practice of screening for disease. Geneva:WHO, 1968.
54. Nuffield Council on Bioethics. Genetic Screening. Ethical Issues. London: Nuffield Council on Bioethics, 1993.
55. Health Council of the Netherlands. Genetic Screening. The Hague: Health Council of The Netherlands, 1994.
56. Chadwick R, ten Have HA, Husted J, et al. Genetic screening and ethics: European perspectives. J Med Philos 1998; 23(3):255-273.
57. Godard B, ten Kate LP, Evers-Kiebooms G, Ayme S. Population genetic screening programmes:principles, techniques, practices, and policies. Eur J Hum Genet 2003; 11(Suppl 2):S49-S87.
58. Van Wijnen AC. De maatschappelijke effecten van genetisch onderzoek. Over misbruik, keuzemogelijkheden en verplichtingen. Medisch Contact 1995; 50:1192-1195.
59. Reinders JS. Moeten wij gehandicapt leven voorkomen? Ethische implicaties van beslissingen over kinderen met een aangeboren of erfelijke aandoening. Utrecht: Nederlandse Vereniging voor Bioethiek, 1996.
60. Reinders JS. The Future of the Disabled in Liberal Society. An Ethical Analysis. Notre Dame: University of Notre Dame Press, 2000.
61. Parens E, Asch A. The disability rights critique of prenatal testing: reflections and recommendations. Parens E, Asch A, eds. Prenatal Testing and Disability Rights. Washington: Georgetown University Press, 2000:3-43.
62. Nelson JL. The meaning of the act: reflections on the expressive force of reproductive decision making and policies. Kennedy Inst Ethics J 1998; 8(2):165-182.
63. Asch A. Prenatal diagnosis and selective abortion: a challenge to practice and policy. Am J Public Health 1999; 89(11):1649-1657.
64. Chadwick R. The perfect baby: introduction. In: Chadwick R, ed. Ethics, Reproduction and Genetic Control. London: Routledge; 1987,:93-135.
65. Den Hartogh GA. Prenatale diagnostiek. De morele bezwaren gewogen. Medisch Contact 1997; 52:1591-1594.
66. Murray J, Cuckle H, Taylor G, Littlewood J, Hewison J. Screening for cystic fibrosis. Health Technol Assess 1999; 3(8):1-104.
67. De Wert GM. Erfelijkheidsonderzoek en ethiek: een gordiaanse knoop. Wijsgerig perspectief 2000; 40(2000):150-156.
68. Health Council of the Netherlands. Prenatale screening: Downsyndroom, neuralebuisdefecten, routine-echoscopie. The Hague: Health Council of the Netherlands, 2001:2001/11.
69. Davis DS. Genetic dilemmas and the child's right to an open future. Hastings Center Report 1997; 27(2):7-15.
70. Clarke AJ. Prenatal genetic screening. Paradigms and perspectives. In: Harper PS, Clarke AJ, eds. Genetics, Society, and Clinical Practice. Abingdon: Bios Scientific Publishers, 1997.
71. De Wert GM, De Wachter MA. Mag ik uw genenpaspoort? Ethische aspecten van dragerschapsonderzoek bij de voortplanting. Baarn: Ambo, 1990.
72. National Consultative Ethics Committee. Congenital Handicaps and Prejudice. Paris:CCNE, 2001:68.
73. Tabor A, Philip J, Madsen M, Bang J, Obel EB, Norgaard-Pedersen B. Randomised controlled trial of genetic amniocentesis in 4606 low-risk women. Lancet 1986; 1(8493):1287-1293.
74. Wald NJ, Kennard A, Hackshaw A, McGuire A. Antenatal screening for Down's syndrome. J Med Screen 1997; 4(4):181-246.
75. Mansfield C, Hopfer S, Marteau TM. Termination rates after prenatal diagnosis of Down syndrome, spina bifida, anencephaly, and Turner and Klinefelter syndromes:a systematic literature review. European Concerted Action: DADA (Decisionmaking After the Diagnosis of a fetal Abnormality). Prenat Diagn 1999; 19(9):808-812.
76. Mulvey S, Wallace EM. Women's knowledge of and attitudes to first and second trimester screening for Down's syndrome. Br J Obstet Gynaecol 2000; 107(10):1302-1305.
77. Weinans MJ, Huijssoon AM, Tymstra T, Gerrits MC, Beekhuis JR, Mantingh A. How women deal with the results of serum screening for Down syndrome in the second trimester of pregnancy. Prenat Diagn 2000; 20(9):705-708.
78. de Graaf IM, Tijmstra T, Bleker OP, van Lith JM. Womens' preference in Down syndrome screening. Prenat Diagn 2002; 22(7):624-629.
79. Alfirevic Z, Neilson JP. Antenatal screening for Down's syndrome. Br Med J 2004; 329(7470):811-812.
80. Health Council of the Netherlands. Prenatale Screening (2): Downsyndroom, neuralebuisdefecten. The Hague: Health Council of The Netherlands; 2004:2004/06.
81. Cuckle H, Arbuzova S. Multi-marker serum screening for chromosomal abnormalities. In: Milunsky A, ed. Genetic Disorders and the Fetus. Diagnosis, Prevention, and Treatment. Baltimore, MD: Johns Hopkins University Press, 2004.
82. Droste S, Bitzer E, Perleth M. HTA des biochemischen Screenings für fetale Chromosomenanomalien und Neurahlrohrdefekte. Bundesgesundheitsbl Gesundheitsforsch Gesundheitsschutz 2001; 44:903-907.
83. Van Lith JM, Vandenbussche F. Stilte rond prenatale screening. Medisch Contact 2003; 58:136.
84. Seror V, Costet N, Ayme S. Dépistage prénatal de la trisomie 21 par marquers sériques maternels: de l'information à la prise de décision des femmes enceintes. J Gynecol Obstet Biol Reprod (Paris) 2000; 29(5):492-500.
85. Green JM, Hewison J, Bekker HL, Bryant LD, Cuckle HS. Psychosocial aspects of genetic screening of pregnant women and newborns: a systematic review. Health Technol Assess 2004; 8(33):iii, ix-iii, 109.
86. Dormandy E, Hooper R, Michie S, Marteau TM. Informed choice to undergo prenatal screening: a comparison of two hospitals conducting testing either as part of a routine visit or requiring a separate visit. J Med Screen 2002; 9(3):109-114.
87. Lidz CW, Appelbaum PS, Meisel A. Two models of implementing informed consent. Arch Intern Med 1988; 148(6):1385-1389.
88. Press N, Browner CH. Risk, autonomy, and responsibility. Informed consent for prenatal testing. Hastings Cent Rep 1995; 25:S9-S12.
89. Sheridan E, Williams J, Caine A, Morgan R, Mason G, Mueller RF. Counselling implications of chromosomal abnormalities other than trisomy 21 detected through a maternal serum screening programme. Br J Obstet Gynaecol 1997; 104(1):42-45.
90. De Wert GM. Prenatale diagnostiek en selectieve abortus. Enkele ethische overwegingen. In: ten Have HA, ed. Ethiek en recht in de gezondheidszorg. Deventer: Kluwer, 1990:121-153.
91. Cirigliano V, Voglino G, Canadas MP, et al. Rapid prenatal diagnosis of common chromosome aneuploidies by QF-PC. Assessment on 18,000 consecutive clinical samples. Mol Hum Reprod 2004; 10(11):839-846.
92. Marteau TM, Dormandy E, Michie S. A measure of informed choice. Health Expect 2001; 4(2):99-108.
93. Vos JM, Offringa M, Bilardo CM, Lijmer JG, Barth PG. [Sensitive and specific screening for detection of spina bifida by echography in the second trimester; systematic review and meta-analysis]. Ned Tijdschr Geneeskd 2000; 144(36):1736-1741.
94. Eurenius K, Axelsson O, Gallstedt-Fransson I, Sjoden PO. Perception of information, expectations and experiences among women and their partners attending a secondtrimester routine ultrasound scan. Ultrasound Obstet Gynecol 1997; 9(2):86-90.
95. Michie S, Smith D, Marteau TM. Prenatal tests: how are women deciding? Prenat Diagn 1999; 19(8):743-748.
96. Eurocat. Prevention of Neural Tube Defects by Periconceptional Folic Acid Supplementation in Europe. Newtownabbey: Eurocat Central Registry, 2003.
97. McConkie-Rosell A, Spiridigliozzi GA, Iafolla T, Tarleton J, Lachiewicz AM. Carrier testing in the fragile X syndrome: attitudes and opinions of obligate carriers. Am J Med Genet 1997; 68(1):62-69.
98. Wald NJ. Couple screening for cystic fibrosis. Lancet 1991; 338(8778):1318-1319.
99. Miedzybrodzka ZH, Hall MH, Mollison J, et al. Antenatal screening for carriers of cystic fibrosis: randomised trial of stepwise v couple screening. Br Med J 1995; 310(6976):353-357.
100. Miedzybrodzka Z, Semper J, Shackley P, Abdalla M, Donaldson C. Stepwise or couple antenatal carrier screening for cystic fibrosis: Women's preferences and willingness to pay. J Med Genet 1995; 32(4):282-283.
101. Henneman L, ten Kate LP. Preconceptional couple screening for cystic fibrosis carrier status: couples prefer full disclosure of test results. J Med Genet 2002; 39(5):E26.
102. Denayer L, Welkenhuysen M, Evers-Kiebooms G, Cassiman JJ, Van den Berghe H. Risk perception after CF carrier testing and impact of the test result on reproductive decision making. Am J Med Genet 1997; 69(4):422-428.
103. Henneman L, Bramsen I, van der Ploeg HM, et al. Participation in preconceptional carrier couple screening: characteristics, attitudes, and knowledge of both partners. J Med Genet 2001; 38(10):695-703.
104. National Consultative Ethics Committee. Le dépistage prénatal géneralisé de la mucoviscidose. Paris: CCNE, 2004:68.
105. Zeuner D, Ades AE, Karnon J, Brown J, Dezateux C, Anionwu EN. Antenatal and neonatal haemoglobinopathy screening in the UK: review and economic analysis. Health Technol Assess 1999; 3(11):1-186.
106. Foster MW, Sharp RR. Race, ethnicity, and genomics: social classifications as proxies of biological heterogeneity. Genome Res 2002; 12(6):844-850.
107. Davies SC, Cronin E, Gill M, Greengross P, Hickman M, Normand C. Screening for sickle cell disease and thalassaemia: a systematic review with supplementary research. Health Technol Assess 2000; 4(3):1-99.
108. Neuenschwander H, Modell B. Audit of process of antenatal screening for sickle cell disorders at a north London hospital. Br Med J 1997; 315(7111):784-785.
109. Delatycki MB, Sheffield LJ, Wake S, Cohen J. Screening approach for fragile X syndrome. Prenat Diagn 2004; 24(1):67-68.
110. Song FJ, Barton P, Sleightholme V, Yao GL, Fry-Smith A. Screening for fragile X syndrome: a literature review and modelling study. Health Technol Assess 2003; 7(16):1-106.
111. de Jong A, de Wert G. Screening op dragerschap van het fragiele-X-syndroom; ethische verkenning. Ned Tijdschr Geneeskd 2002; 146(13):611-615.
112. Hagerman PJ, Hagerman RJ. The fragile-X premutation: a maturing perspective. Am J Hum Genet 2004; 74(5):805-816.
113. Wald NJ, Morris JK. A new approach to antenatal screening for fragile X syndrome. Prenat Diagn 2003; 23(4):345-351.
114. Costa JM, Benachi A, Gautier E, Jouannic JM, Ernault P, Dumez Y. First-trimester fetal sex determination in maternal serum using real-time PCR. Prenat Diagn 2001; 21(12):1070-1074.
115. Rijnders RJ, Christiaens GC, Van der Smagt J, De Haas M, Van der Schoot CE, Ralston AS. Ethical implications of early non-invasive fetal sex determination. In: Rijnders RJ, ed. Cell-free Fetal DNA in Maternal Plasma. Thesis, Utrecht University, Utrecht, 2003:111-124.
116. Pesso R, Berkenstadt M, Cuckle H, et al. Screening for fragile X syndrome in women of reproductive age. Prenat Diagn 2000; 20(8):611-614.
117. Ryynanen M, Heinonen S, Makkonen M, Kajanoja E, Mannermaa A, Pertti K. Feasibility and acceptance of screening for fragile X mutations in low-risk pregnancies. Eur J Hum Genet 1999; 7(2):212-216.
118. Tejada MI, Duran M. Screening for female fragile X premutation and full mutation carriers. Community Genet 1999; 2(1):49-50.
119. Kallinen J, Heinonen S, Mannermaa A, Ryynanen M. Prenatal diagnosis of fragile X syndrome and the risk of expansion of a premutation. Clin Genet 2000; 58(2):111-115.
120. Murray J, Cuckle H, Taylor G, Hewison J. Screening for fragile X syndrome. Health Technol Assess 1997; 1(4):i-71.
121. Pembrey ME, Barnicoat AJ, Carmichael B, Bobrow M, Turner G. An assessment of screening strategies for fragile X syndrome in the UK. Health Technol Assess 2001; 5(7):1-95.
122. Gevers JK. Toepassing van de genetica in het kader van de hulpverlening. In: Commissie genetica, ed. Toepassing van de genetica in de gezondheidszorg. Gevolgen van de ontwikkelingen voor de huidige wet- en regelgeving. Den Haag: ZonMw, 2003:11-25.
123. Howlet MJ, Avard D, Knoppers BM. Physicians and genetic malpractice. Med Law 2002; 21:661-680.
124. Ossorio PN. Prenatal genetic testing and the courts. In: Parens E, Asch A, eds. Prenatal testing and disability rights. Washington, DC: Georgetown University Press, 2000:308-333.
125. Duguet AM. Wrongful life: the recent French Cour de Cassation decisions. Eur J Health Law 2002; 9:139-163.
126. Bundesgerichtshof VI Zivilsenat. Fundstelle: BGHZ 1983; 86:240.
127. Gevers JK, De Wert GM. De zaak Kelly: moet de wetgever grenzen stellen? Ned Tijdschr Obstet Gynaecol 2003; 116:172-174.
128. Stolker C, Sombroek-van Doorm MP. De wrongful life-vordering: schadevergoeding of euthanasie?. Ned Tijdschr Burgerlijk Recht 2003; 20:496-506.
129. Royal Commission on Civil Liability and Compensation for Personal Injury. Royal Commission on Civil Liability and Compensation for Personal Injury. Civil Liability and Compensation for Personal Injury. Report, Vol. 1. London: HSMO, 1978:Cmnd.7045-I.
130. L'Assemblée nationale et le Sénat. LOI no. 2002-303 du 4 mars 2002 relative aux droits des malades et à la qualité du système de santé, 2002.
131. Hoge Raad der Nederlanden. Uitspraak 18 maart 2005. Eerste Kamer, nr C03/206HR, 2005. (Accessed March 18, 2005, at www.rechtspraak.nl.).
132. Health Council of the Netherlands. Het ongeboren kind als patiënt. Invasieve diagnostiek en behandeling van de foetus. Den Haag: Health Council of The Netherlands, 1990:1990/05.
133. Kumar S, O'Brien A. Recent developments in fetal medicine. Br Med J 2004; 328(7446):1002-1006.
134. Adzick NS, Sutton LN, Crombleholme TM, Flake AW. Successful fetal surgery for spina bifida. Lancet 1998; 352(9141):1675-1676.
135. Bruner JP, Tulipan N, Paschall RL, et al. Fetal surgery for myelomeningocele and the incidence of shunt-dependent hydrocephalus. J Am Med Assoc 1999; 282(19):1819-1825.
136. Sutton LN, Adzick NS, Bilaniuk LT, Johnson MP, Crombleholme TM, Flake AW. Improvement in hindbrain herniation demonstrated by serial fetal magnetic resonance imaging following fetal surgery for myelomeningocele. J Am Med Assoc 1999; 282(19):1826-1831.
137. van Heurn LW, Harrison MR. Fetal surgery: for selected patients. The experiences of the Fetal Treatment Center in San Francisco. Ned Tijdschr Geneeskd 2003; 147(19):900-904.
138. Quintero RA, Carreño C. Operative fetoscopy. In: Rodeck CH, Whittle MJ, eds. Fetal Medicine: Basic Science and Clinical Practice. London: Churchill Livingstone, 1999:755-769.
139. Surbek DV, Holzgreve W, Nicolaides KH. Haematopoietic stem cell transplantation and gene therapy in the fetus: ready for clinical use? Hum Reprod Update 2001; 7(1):85-91.
140. Flake AW. Stem cell and genetic therapies for the fetus. Semin Pediatr Surg 2003; 12(3):202-208.
141. Touraine JL, Raudrant D, Golfier F, et al. Reappraisal of in utero stem cell transplantation based on long-term results. Fetal Diagn Ther 2004; 19(4):305-312.
142. Coutelle C, Themis M, Waddington S, et al. The hopes and fears of in utero gene therapy for genetic disease-a review. Placenta 2003; 24(Suppl B):S114-S121.
143. Zanjani ED, Anderson WF. Prospects for in utero human gene therapy. Science 1999; 285(5436):2084-2088.
144. Fletcher JC, Richter G. Human fetal gene therapy: moral and ethical questions. Hum Gene Ther 1996; 7(13):1605-1614.
145. Chervenak FA, McCullough LB. The fetus as a patient: an essential ethical concept for maternal-fetal medicine. J Matern Fetal Med 1996; 5(3):115-119.
146. Chervenak FA, McCullough LB. A comprehensive ethical framework for fetal research and its application to fetal surgery for spina bifida. Am J Obstet Gynecol 2002; 187(1):10-14.
147. Bewley S. Ethical issues in maternal-fetal medicine. In: Rodeck CH, Whittle MJ, eds. Fetal Medicine: Basic Science and Clinical Practice. London: Chrchill Livingstone, 1999:265-279.
148. Lyerly AD, Gates EA, Cefalo RC, Sugarman J. Toward the ethical evaluation and use of maternal-fetal surgery. Obstet Gynecol 2001; 98(4):689-697.
149. Burger IM, Wilfond BS. Limitations of informed consent for in utero gene transfer research: implications for investigators and institutional review boards. Hum Gene Ther 2000; 11(7):1057-1063.
150. Caplan AL, Wilson JM. The ethical challenges of in utero gene therapy. Nat Genet 2000; 24(2):107.
151. Billings PR. In utero gene therapy: the case against. Nat Med 1999; 5(3):255-256.
152. Wenstrom KD. Fetal surgery for congenital diaphragmatic hernia. N Engl J Med 2003; 349(20):1887-1888.
153. Senat MV, Deprest J, Boulvain M, Paupe A, Winer N, Ville Y. Endoscopic laser surgery versus serial amnioreduction for severe twin-to-twin transfusion syndrome. N Engl J Med 2004; 351(2):136-144.
154. Harrison MR, Keller RL, Hawgood SB, et al. A randomized trial of fetal endoscopic tracheal occlusion for severe fetal congenital diaphragmatic hernia. N Engl J Med 2003; 349(20):1916-1924.
155. Sicard D. Ethical questions raised by in utero therapeutics with stem cells and gene therapy. Fetal Diagn Ther 2004; 19(2):124-126.